NF-κB, chemokine gene transcription and tumour growth

Nature Reviews Immunology

Volumn 2, Issue 9, 2002, Pages 664-674

  Richmond, Ann ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CELL PROTEIN; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; ENHANCEOSOME; GENE PRODUCT; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 8; PHOSPHOTRANSFERASE; PROTEIN KINASE B; RAS PROTEIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANOXIA; CANCER THERAPY; CARCINOGENESIS; CELL ORGANELLE; DIFFERENTIAL DISPLAY; DNA MICROARRAY; ENZYME ACTIVATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCID MOUSE; TATA BOX; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CHEMOKINES; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 0036717195     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri887     Document Type: Review

References (123)

1. Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242 (2000).
2. Luster, A. D. The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol. 14, 129-135 (2002).
3. Homey, B., Muller, A. & Zlotnik, A. Chemokines: agents for the immunotherapy of cancer. Nature Rev. Immunol. 2, 175-184 (2002).
4. Chensue, S. W. Molecular machinations, chemokine signals in host-pathogen interactions. Clin. Microbiol. Rev. 14, 821-835 (2001).
5. Devalaraja, M. N. & Richmond, A. Multiple chemotactic factors, fine control or redundancy? Trends Pharmacol. Sci. 20, 151-156 (1999).
6. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001). This article reviews the role of chemokines as regulators of tumour growth and metastasis, or the inhibition of tumour growth.
7. Strieter, R. M. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nature Immunol. 2, 285-286 (2001). A review of opposing roles of angiogenic and angiostatic CXC-chemokines in tumour growth.
8. Payne, A. S. & Cornelius, L. A. The role of chemokines in melanoma tumor growth and metastasis. J. Invest Dermatol. 118, 915-922 (2002). This article reviews the roles of CXCL1, CXCL8 and CCL5 in melanoma.
9. Luan, J. et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression J. Leukocyte Biol. 62, 588-597 (1997).
10. Robledo, M. M. et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J. Biol. Chem. 276, 45098-45105 (2001).
11. Wiley, H. E., Gonzalez, E. B., Maki, W., Wu, M. T. & Hwang, S. T. Expression of CC-chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl Cancer Inst. 93, 1638-1643 (2001).
12. Sunwoo, J. B. et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous-cell carcinoma. Clin. Cancer Res. 7, 1419-1428 (2001).
13. Dong, G. et al. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis and the NF-κB signal pathway. Cancer Res. 61, 4797-4808 (2001).
14. Cusack, J. C. Jr et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341, implications for systemic nuclear factor-κB inhibition. Cancer Res. 61, 3535-3540 (2001). This article shows that use of the proteasome inhibitor inhibition of tumour growth when it is used in combination with the chemotherapeutic agent CPT-11.
15. Sprenger, H., Lloyd, A. R., Meyer, R. G., Johnston, J. A. & Kelvin, D. J. Genomic structure, characterization, and identification of the promoter of the human IL-8 receptor A gene. J. Immunol. 153, 2524-2532 (1994).
16. Bonecchi, R. et al. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J. Immunol. 164, 3862-3869 (2000).
17. Lloyd, A. R. et al. Granulocyte-colony stimulating factor and lipopolysaccharide regulate the expression of interleukin-8 receptors on polymorphonuclear leukocytes. J. Biol. Chem. 270, 28188-28192 (1995).
18. Ivarsson, K., Ekerydh, A., Fyhr, I. M., Janson, P. O. & Brannstrom, M. Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas. Acta Obstet. Gynecol. Scand. 79, 777-784 (2000).
19. Li, A., Varney, M. L. & Singh, R. K. Expression of interleukin-8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin. Cancer Res. 7, 3298-3304 (2001).
20. Azenshtein, E. et al. The CC-chemokine RANTES in breast carcinoma progression, regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 62, 1093-1102 (2002).
21. Mrowietz, U. et al. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br. J. Cancer 79, 1025-1031 (1999).
22. Genin, P., Algarte, M., Roof, P., Lin, R. & Hiscott, J. Regulation of RANTES chemokine gene expression requires cooperativity between NF-κB and IFN-regulatory factor transcription. J. Immunol. 164, 5352-5361 (2000).
23. Yang, J. M. & Richmond, A. Constitutive IKK activity correlates with NF-κB activation in human melanoma cells. Cancer Res. 61, 4901-4909 (2001). This article shows that melanoma cell lines have constitutive IKK activity, and also constitutive phosphorylation of p65, which results in constitutive NF-κB transcriptional activity and enhanced expression of chemokines. The article also shows that the chemokine CXCL1 contributes to the constitutive activation of IKK through an autocrine loop.
24. Yang, C.-R. et al. Coordinate modulation of Sp1, NF-κB and p53 in confluent human malignant melanoma cells after ionizing radiation. FASEB J. 14, 379-392 (2000).
25. Vanden Berghe, W., De Bosscher, K., Boone, E., Plaisance, S. & Haegeman, G The nuclear factor-κB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J. Biol. Chem. 274, 32091-32098 (1999).
26. Huang, S., De Guzman, A., Bucana, C. D. & Fidler, I. J. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-κB activity. Cytokines Cell. Mol. Ther 6, 9-17 (2000).
27. Kunz, M. et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am. J. Pathol. 155, 753-763 (1999).
28. Huang, S., DeGuzman, A., Bucana, C. D. & Fidler, I. J. Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin. Cancer Res. 6, 2573-2581 (2000).
29. Bakker, T. R., Reed, D., Renno, T. & Jongeneel, C. V. Efficient adenoviral transfer of NF-κB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis. Int. J. Cancer 80, 320-323 (1999).
30. Wang, D. et al. MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene 19, 4647-4659 (2000).
31. Baldwin, A. S. Control of oncogenesis and cancer-therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 107, 241-246 (2001). An excellent review of NF-κB, its role in cancer and the potential for therapeutic intervention using inhibitors of NF-κB.
32. Beg, A. A. et al. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: a mechanism for cytoplasmic retention Genes Dev. 10, 1899-1913 (1992).
33. Didonato, J., Mercurio, F. & Kann, M. Phosphorylation of IκB-α precedes but is not sufficient for its dissociation from NF-κB. Mol. Cell. Biol. 15, 1302-1311 (1995).
34. DiDonato, J. et al Mapping of the inducible I-κB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell. Biol. 16, 1295-1304 (1996).
35. Pando, M. P. & Verma, I. M. Signal-dependent and -independent degradation of free and NF-κB-bound IκB-α. J. Biol. Chem. 275, 21278-21286 (2000).
36. Ung, L., Cao, Z. D. & Goeddel, D. V. NF-κB-inducing kinase activates IKK-α by phosphorylation of ser-176. Proc. Natl Acad. Sci. USA 95, 3792-3797 (1998). An introduction to the biological role of NIK as an activator of IKKα.
37. Nakano, H. et al. Differential regulation of I-κB kinase-α and -β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase ERK kinase kinase. Proc. Natl Acad. Sci. USA 95, 3537-3542 (1998).
38. Smith, C. et al. NF-κB-inducing kinase is dispensable for activation of NF-κB in inflammatory settings but essential for lymphotoxin-β receptor activation of NF-κB in primary human fibroblasts. J. Immunol. 167, 5895-5903 (2001).
39. Perkins, N. D. et al. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275, 523-527 (1997).
40. Shattuck-Brandt, R. L. & Richmond, A. Enhanced degradation of I-κB-α contributes to endogenous activation of NF-κB in Hs294T melanoma cells. Cancer Res. 57, 3032-3039 (1997).
41. Shattuck, R. L., Wood, L. D., Jaffe, G. J. & Richmond, A. MGSA/GRO transcription is differentially regulated in normal retinal pigment epithelial and melanoma cells. Mol. Cell. Biol. 14, 791-802 (1994).
42. Wood, L. D., Farmer, A. A. & Richmond, A. HMGI (Y), and SP1 in addition to NF-κB regulate transcription of the MGSA/GROα gene. Nucleic Acids Res, 23, 4210-4219 (1995).
43. Wood, L. D. & Richmond, A. Constitutive and cytokine-induced expression of the melamoma growth stimulatory activity/GROα gene requires both NF-κ constitutive factors. J Biol. Chem. 270, 30619-30626 (1995).
44. Kondo, S., Kono, T. Sauder, D. N. & McKenzie, R. C. IL-8 gene expression and production in human keratinocytes and their modulation by UVB. J. Invest. Dermatol. 101. 690-694 (1993).
45. Wang, Y. & Becker, D. Antisense targeting of bFGF and FGF receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nature Med. 8, 887-893 (1997).
46. Shih, I.-M, & Herlyn, M. Autocrine and paracrine roles for growth factors in melanoma. In Vitro 8, 113-124 (1994).
47. Gilmore, T. D., Koedood, M., Piffat, K. A. & White, D. W. Rel/NF-κB/lκB proteins and cancer. Oncogene 13, 1367-1378 (1996).
48. Karin, M. & Lin, A. NF-κB at the crossroads of life and death. Nature Immunol. 3, 221-227 (2002). This article provides an up-to-date view of the role of NF-κB activation in the modulation of factors that are involved in apoptosis and cell survival.
49. Dejardin, E. et al. Highly expressed p100/p52 (NF-κB2) sequesters other NF-κB-releted proteins in the cytoplasm of human breast cancer cells. Oncogene 11, 1835-1841 (1995).
50. Tamatani, T. et al. Enhanced IκB kinase activity is responsible for the augmented activity of NF-κB in human head and neck carcinoma cells. Cancer Lett. 171, 165-172 (2001).
51. Mukhopadhyay, T., Roth, J. A. & Maxwell, S. A. Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma. Oncogene 11, 999-1003 (1995).
52. Bours, V., Dejardin, E., Goujon-Letawe, P., Merville, M. P. & Castronov, V. The NF-κB transcription factor and cancer: high expression of NF-κB and IκB-related proteins in tumor cell lines. Biochem. Pharmacol. 47, 145-149 (1994).
53. Budunova, I. V. et al. Increased expression of p50-NF-κB and constitutive activation of NF-κB transcription factors during mouse skin carcinogenesis. Oncogene 18, 7423-7431 (1999).
54. Visconti, R. et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF-κB p65 protein expression. Oncogene 15, 1987-1994 (1997).
55. Sovak, M. A. et al. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100, 2952-2960 (1997).
56. Devalaraja, M., Wang, D. Z., Ballard D. W. & Richmond, A. Elevated constitutive IKK activity and IκB-α phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GROα transcription. Cancer Res. 59, 1372-1377 (1999).
57. Dhawan, P. & Richmond, A. The role of endogenous NIK and MEKK1 in the constitutive activation of NF-κB in human melanomas. J. Biol. Chem. 277, 7920-7928 (2002). This study shows that, in human melanoma, there is constitutive activation of NIK, and that blocking NIK blocks the constitutive activation of NF-κB in melanoma cells. Moreover, this NIK-mediated effect on NF-κB activity requires the activation of MEKK1 and ERK1/ERK2.
58. Cusack, J., Liu, R. & Baldwin, A. Inducible chemoresistance to 7-ethyl-10-[4-(1-pipeddino)-1-pipendino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation Cancer Res. 60, 2323-2330 (2000).
59. Budunova, I. V. et al. Increased expression of p59-NF-κB and constitutive activation of NF-κB transcription factors during mouse skin carcinogenesis. Oncogene 19, 3003-3012 (2000).
60. Mayo, M. W. & Baldwin, A. S. The transcription factor NF-κB, control of oncogenesis and cancer-therapy resistance. Biochim. Biophys. Acta 1470, M55-M62 (2000).
61. Malinin, N. L., Boldin, M. P., Kovalenko, A. V. & Wallach, D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385, 540-544 (1997).
62. Xiao, G., Harhaj, E. W. & Sun, S. C. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol. Cell 7, 401-409 (2001).
63. Cogswell, P. C., Guttridge, D. C., Funkhouse, W. K. & Baldwin, A. S. Jr. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene 19, 1123-1131 (2000).
64. Senftleben, U. et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 293, 1495-1499 (2001).
65. Fagarasan, S. et al. Alymphophasia (aly)-type nuclear factor-λB-inducing kinase (NIK) causes defects in secondary lymphoid tissue chemokine receptor signaling and homing of peritoneal cells to the gut-associated lymphatic tissue system. J. Exp. Med. 191, 1477-1486 (2000). This article shows that loss of NIK not only affects signalling through the lymphotoxin-β receptor, but also alters the response to chemokines, which indicates that chemokine receptors might also activate NIK.
66. Zhong, H., Voll, R. E. & Ghosh, S. Rearranged NF-κB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Mol. Cell 1, 661-671 (1998).
67. Bird, T. A., Schooley, K., Dower, S. K., Hagen, H. & Virca, G. D. Activation of nuclear transcription factor NF-κB by interleukin-1 is accompanied by casein-kinase-II-mediated phosphorylation of the p65 subunit. J. Biol. Chem. 272. 32606-32612 (1997).
68. Sakurai, H., Chiba, H., Miyoshi, H., Sugita, T. & Toriumi, W. IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 274, 30353-30356 (1999).
69. Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H. & Stark, G. R. Distinct roles of the IκB kinase α- and β-subunits in liberating nuclear factor-κB (NF-κB) from IκB and in phosphorylating the p65 subunit of NF-κB. J. Biol. Chem. 277, 3863-3869 (2002). This article shows the role of AKT in the activation of IKKα, which potentially phosphorylates the p65 subunit of NF-κB to potentiate its transactivating capacity.
70. Li, X. & Stark, G. R. NF-κB-dependent signaling pathways. Exp. Hematol. 30, 285-296 (2002).
71. Delhase, M., Li, N. & Karin, M. Kinase regulation in inflammatory response. Nature 406, 367-368 (2000).
72. Koul, D., Yao, Y., Abbruzzese, J. L., Yung, W. K. & Reddy, S.A. Tumor suppressor MMAC/PTEN inhibits cytokine induced NF-κB activation without interfering with the IκB degradation pathway. J. Biol. Chem. 276, 11402-11408 (2001).
73. Madrid, L. V. Mayo, M. W., Reuther, J. Y. & Baldwin, A. S. Jr. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 276, 18934-18940 (2001).
74. Celebi, J. T. Shendrik, I., Silvers, D. N. & Peacocke, M. Identification of PTEN mutations in metastatic melanoma specimens. J. Med. Genet. 37, 653-657 (2000).
75. Zhou, X. P. et al. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 157, 1123-1128 (2000).
76. Mayo, M. W. et al. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278, 1812-1815 (1997).
77. Finco, T S. et al. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272, 24113-24116 (1997).
78. Norris, J. L. & Baldwin, A. S. Oncogenic Ras enhances NF-κB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J. Biol. Chem. 274, 13841-13846 (1999).
79. Troppmair, J., Hartkamp, J. & Rapp, U. R. Activation of NF-κB by oncogenic Raf in HEK293 cells occurs through autocrine recruitment of the stress kinase cascade. Oncogene 17, 685-690 (1998).
80. Yin, M. J. et al. HTLV-1 Tax protein binds to MEKK1 to stimulate IκB kinase activity and NF-κB activation. Cell 93, 875-884 (1998).
81. Chu, Z., DiDonato, J., Hawiger, J. & Ballard, D. The tax oncogene of human T-cell leukemia virus type 1 associates with and persistently activates IκB kinases containing IKKα and IKKβ. J. Biol. Chem. 273, 15891-15894 (1998).
82. Geleziunas, R. et al. Human T-cell leukemia virus type 1 Tax induction of NF-κB involves activation of the IκB kinase-α (IKKα) and IKKβ cellular kinases. Mol. Cell. Biol. 18, 5157-5165 (1998).
83. Mosialos, G. The role of Rel/NF-κB proteins in viral oncogenesis and the regulation of viral transcription. Semin. Cancer Biol. 8, 121-129 (1997).
84. LaPorta, C. A. & Camolli, R. PKC-dependent modulation of IκBα-NF-κB pathway in low metastatic B16F1 murine melanoma cells and in highly metastatic BL6 cells. Anticancer Res. 18, 2591-2597 (1998).
85. Biswas, D. K. et al. The nuclear factor-κB (NF-κB): a potential therapeutic target for estrogen receptor-negative breast cancers. Proc. Natl. Acad. Sci. USA 98, 10386-10391 (2001).
86. Wilson, L., Szabo, C. & Salzman, A. L Protein kinase-C-dependent activation of NF-κB in enterocytes is independent of IκB degradation. Gastroenterology 117, 106-114 (1999).
87. Han, Y., Meng, T., Murray, N. R., Fields, A. P. & Brasier, A. R. Interleukin-1-induced nuclear factor-κB-IκB-α autoregulatory feedback loop in hepatocytes A role for protein kinase Cα in post-transcriptional regulation of IκB-α resynthesis. J. Biol. Chem. 274, 939-947 (1999).
88. Anrather, J., Csizmadia, V., Soares, M. P. & Winkler, H. Regulation of NF-κB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase Cζ in primary endothelial cells. J. Biol Chem. 274, 13594-13603 (1999).
89. Wang, D. & Richmond, A. NF-κB activation by the CXC-chemokine MGSA/GROα involves the MEKK1/p38 MAP kinase pathway. J. Biol. Chem. 276, 3650-3659 (2001).
90. Richmond, A. & Thomas, H. G. Melanoma growth stimulatory activity, a novel growth factor with a tissue distribution not restricted to melanoma tissue. J Cell. Biochem. 36, 185-198 (1986).
91. Singh, R. K. et al. Expression of interleukin-8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54, 3242-3247 (1994).
92. Singh, R. K. et al. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin-8, Cancer Res 55, 3669-3674 (1995).
93. Schadendorf, D. et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151, 2267-2675 (1993).
94. Schadendorf, D et al. Metastatic potential of human melanoma cells in nude mice - characterization of phenotype, cytokine secretion and tumor-associated antigens. Br. J. Cancer 74, 194-199 (1996).
95. Loukinova, E. et al. Growth-regulated oncogene-α expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC-receptor-2-dependent mechanism. Oncogene 19, 3477-3486 (2000).
96. Matsusaka, T et al. Transcription factors NF-IL-6 and NF-κB synergistically activate transcnption of the inflammatory cytokines, interleukin-6 and interleukin-8. Proc. Natl Acad. Sci. USA 90, 10193-10197 (1993).
97. Balentien, E. et al. Effects of MGSA/GROα on melanacyte transformation. Oncogene 6, 1115-1124 (1991).
98. Nirodi, C. S. & Richmond, A. Role of poly (ADP-ribose) polymerase (PARP) in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene. J. Biol Chem. 276, 9366-9374 (2001). This article shows that PARP participates with NF-κB in the modulation of transcription of CXCL1.
99. Nirodi, C. S. et al. The 170-kDa CCAAT displacement protein (CDP/Cut) selectively binds the IUR cis-element in the CXCL1 promoter The role of CDP in the negative regulation of CXCL1 gene expression. J. Biol. Chem. 276, 9366-9374 (2001). This study further defines the CXCL1 enhanceosome and shows that binding of the transcriptional repressor CDP to an element adjacent to the NF-κB. binding site represses the transcription of CXCL1.
100. Hassa, P. O. & Hottiger, M. O. A role of poly (ADP-ribose) polymerase in NF-κB transcriptional activation. J. Biol. Chem. 380, 953-959 (1999).
101. Ludlow, C., Choy R. & Blochlinger, K. Functional analysis of Drosophila and mammalian Cut proteins in flies. Dev. Biol. 178, 149-159 (1996).
102. Coqueret, O., Beruhe, G. & Nepveu, A. The mammalian Cut homeodamain protein functions as a cell-cycle-dependent transcriptional repressor which downmodulates p21WAF1/CIP1/SDI1 in S phase. EMBO J. 17, 4680-4694 (1998).
103. Mailly, F. G. et al. The human Cut homeodomain protein can repress gene expression by two distinct mechanisms: active repression and competition for binding-site occupancy. Mol. Cell. Biol. 16, 5346-5357 (1996).
104. Li, S. et al. Transcriptional repression of the cystic fibrosis transmembrane conductance regulator gene, mediated by CCAAT displacement protein/Cut hamolog, is associated with histone deacetylation. J. Biol. Chem. 274, 7803-7815 (1999).
105. Li, S., Aufiero, B., Schlitz, R. L. & Walsh, M. J. Regulation of the homeodomain CCAAT displacement/Cut protein function by histone acetyltransferases p300/CREB-binding protein (CBP)-associated factor and CBP. Proc. Natl Acad. Sci. USA 12, 1627-1631 (2000).
106. Xiao, H. Hasegawa, T. & Isobe, K. p300 collaborates with Sp1 and Sp3 in p21 (Waf1/Cip1) promoter activation induced by histone deacetyase inhibitor. J. Biol. Chem. 275, 1371-1376 (2000).
107. Kundu, T. K. et al. Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300 Mol. Cell. Biol. 6, 551-561 (2000). This article shows the role of p300 in acetylation of histones and the stabilization of the transcriptional machinery.
108. Bottazzi, B., Walter, S., Govoni, D., Colotta, F. & Mantovani, A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth and susceptibility to IL-2 therapy of murine melanoma. J. Immunol. 148, 1280-1285 (1992).
109. Nakashima, E. et al. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm. Res. 12, 1598-1604 (1995).
110. Berman, K. S. et al. Sulindac enhances tumor necrosis factor-α-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-κB. Clin. Cancer Res. 8, 354-360 (2002).
111. May, M. J. et al. Selective inhibition of NF-κB activation by a peptide that blocks the Interaction of NEMO with the IκB kinase complex. Science 289, 1550-1554 (2000).
112. Yamamoto, Y. & Gaynor, R. B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin Invest. 107, 135-142 (2001). This article emphasizes the available data that indicate that, by developing methods of disrupting the NF-κB pathway, new advances can be made in the therapeutic intervention of acute and chronic inflammatory conditions, as well as malignancies.
113. Hideshima, T. et al. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 217, 16639-16647 (2002).
114. Tan, C. & Waldmann, T. A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 62, 1083-1086 (2002).
115. Adams, J. Proteasome inhibition, a novel approach to cancer therapy. Trends Mol. Med. 8, 49-54 (2002). This article reviews the current status of the use of proteasome inhibitors to block tumour growth.
116. Zhang, J., Chang, C. C., Lombardi, L., Dalla-Favera, R. Rearranged NF-κB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 9, 1931-1937 (1994).
117. Higgins, K. A. et al. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl Acad. Sci. USA 90, 9901-9905 (1993).
118. Shah, S. A. et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 82, 110-122 (2001).
119. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P. & Aggarwal, B. B. Curcumin downregulates cell-survival mechanisms in human prostate cancer cell lines. Oncogene 20, 7597-7609 (2001).
120. Nourbakhsh, M. et al. The NF-κB repressing factor is involved in basal repression and interleukin (IL)-1-induced activation of IL-8 transcription by binding to a conserved NF-κB-flanking sequence element. J. Biol. Chem. 276, 4501-4508 (2001). This article models the components of the enhanceosome for CXCL8 and shows that a transcriptional repressor binds to an element flanking the NF-κB element. So, the models for the transcription of CXCL8, CXCL1 and IL-6 are similar.
121. Stein, B., Cogswell, P. S. & Baldwin, A. S. Functional and physical associations between NF-κB and C/EBP family members: a Rel domain-bZIP interaction. Mol. Cell Biol. 13, 3964-3974 (1993).
122. Li, S., Auflero, B., Schiltz, R. L. & Walsh, M. J. Regulation of the homeodomain CCAAT displacement/Cut protein function by histone acetyltransferases p300/CREB-binding protein (CBP)-associated factor and CBR Proc. Natl Acad. Sci. USA 97, 7166-7171 (2000).
123. International Union of Immunological Societies/World Health Organization Subcommittee on Chemokine Nomenclature. Chemokine/chemokine receptor nomenclature. J. Leukocyte Biol. 70, 465-466 (2001).